72 related articles for article (PubMed ID: 7995763)
21. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
Treat J; Johnson E; Langer C; Belani C; Haynes B; Greenberg R; Rodriquez R; Drobins P; Miller W; Meehan L; McKeon A; Devin J; von Roemeling R; Viallet J
J Clin Oncol; 1998 Nov; 16(11):3524-7. PubMed ID: 9817270
[TBL] [Abstract][Full Text] [Related]
22. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
23. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D
Cancer Chemother Pharmacol; 1999; 43(5):402-8. PubMed ID: 10100596
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
26. [Response of regional vascular beds to adrenaline administration (author's transl)].
Antal J
Bratisl Lek Listy; 1982 Apr; 77(4):385-93. PubMed ID: 7093747
[No Abstract] [Full Text] [Related]
27. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
Olive PL; Vikse CM; Banath JP
Cancer Res; 1996 Oct; 56(19):4460-3. PubMed ID: 8813141
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
[TBL] [Abstract][Full Text] [Related]
29. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
Williamson SK; Crowley JJ; Lara PN; McCoy J; Lau DH; Tucker RW; Mills GM; Gandara DR;
J Clin Oncol; 2005 Dec; 23(36):9097-104. PubMed ID: 16361616
[TBL] [Abstract][Full Text] [Related]
30. The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.
Masunaga S; Sakurai Y; Nagata K; Suzuki M; Maruhashi A; Kinashi Y; Nagasawa H; Uto Y; Hori H; Ono K
Br J Radiol; 2006 Dec; 79(948):991-8. PubMed ID: 16916808
[TBL] [Abstract][Full Text] [Related]
31. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
32. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
33. [Influence of d-tubocurarine on the vasomotor action of acetylcholine in the perfused toad hindlimbs].
Hurusawa S; Simada Y; Higasihara Y; Sibata M
Kumamoto Igakkai Zasshi; 1966 Dec; 40(12):1303-6. PubMed ID: 6013629
[No Abstract] [Full Text] [Related]
34. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
Durand RE; Olive PL
Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.
Masunaga S; Tano K; Watanabe M; Kashino G; Suzuki M; Kinashi Y; Ono K; Nakamura J
Br J Radiol; 2009 May; 82(977):392-400. PubMed ID: 19153181
[TBL] [Abstract][Full Text] [Related]
36. The influence of tumor blood flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia.
Vaupel PW
Klin Padiatr; 1997; 209(4):243-9. PubMed ID: 9293457
[TBL] [Abstract][Full Text] [Related]
37. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
[TBL] [Abstract][Full Text] [Related]
38. Advancement of antiangiogenic and vascular disrupting agents combined with radiation.
Citrin D; Camphausen K
Cancer Treat Res; 2008; 139():153-71. PubMed ID: 18236716
[No Abstract] [Full Text] [Related]
39. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
Senan S; Rampling R; Graham MA; Wilson P; Robin H; Eckardt N; Lawson N; McDonald A; von Roemeling R; Workman P; Kaye SB
Clin Cancer Res; 1997 Jan; 3(1):31-8. PubMed ID: 9815534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
